Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 17Neoplasm Metastasis 7Melanoma 6Kidney Neoplasms 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Lung Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Multiple Myeloma 1Meningioma 1

Interventions

pembrolizumab 6Drug Therapy 3Cyclophosphamide 3spartalizumab 2fludarabine 2Sirolimus 2Riluzole 2Oncolytic Virotherapy 2Ipilimumab 2Blood Specimen Collection 2vofatamab 1tocilizumab 1saracatinib 1poly ICLC 1pertuzumab 1pazopanib 1liposomal doxorubicin 1ixabepilone 1fludarabine phosphate 1enzalutamide 1durvalumab 1cediranib 1brodalumab 1atezolizumab 1aldesleukin 1advexin 1Ultrasonography 1Tissue Banks 1TKM-080301 1Ritonavir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × fludarabine phosphate × Breast × Clear all
NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡